OptimizeRx Corporation — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; financial statements are unaudited. OptimizeRx is a digital health company providing communications solutions connecting life-sciences companies, healthcare providers, and patients.
Key financial results
| Metric | Q1 2021 | Q1 2020 | Change / context |
|---|---|---|---|
| Revenue | $11.23 million | $7.58 million | Up 48%; growth across messaging products |
| Gross profit | $6.12 million | $4.34 million | Gross margin 54.5%, versus 57.3% |
| Operating expenses | $6.76 million | $6.60 million | Up about 2.5% |
| Operating loss | $638,308 | $2.26 million | Loss narrowed |
| Net loss | $637,377 | $2.20 million | Basic and diluted loss per share: $0.04 vs. $0.15 |
| Operating cash flow | $1.67 million provided | $3.74 million used | Improved, partly reflecting receivable collections and working-capital movements |
| Cash and cash equivalents | $82.28 million | $10.52 million at Dec. 31, 2020 | Increase included public-offering proceeds |
| Working capital | About $95 million | About $23 million at Dec. 31, 2020 | Current ratio about 19:1 vs. 3:1 |
Margins and expenses: Cost of revenue rose to about 45% of revenue from 43%, which management attributed to solution and delivery-partner mix. Operating expenses increased modestly as the company expanded its team and invested in products and growth; lower travel, consulting, and professional fees partly offset increases in salaries, data, and integration and exclusivity costs.
Liquidity and debt: Total liabilities were $5.74 million, including $424,428 of lease liabilities; the filing reports no borrowings. The company raised $70.67 million net in a public stock offering and received $1.12 million from option exercises, partly offset by a $1.61 million acquisition earnout payment. Management said no earnout payments remained and it did not anticipate needing additional capital for operating or growth plans, while noting that acquisitions or strategic opportunities could require capital.
Material changes and outlook
- Revenue increased 48% year over year, while the net loss narrowed substantially. Operating expenses grew more slowly than revenue, which management said reflected operating leverage.
- Common shares outstanding increased to 17,260,588 at March 31, 2021, from 15,223,340 at year-end, including 1,523,750 shares issued in the public offering and shares issued through option exercises.
- Management expected revenue to continue growing during 2021, citing new enterprise clients, expanded distribution, pharmaceutical brands, and messaging solutions. It expected gross margin to improve during the year, with a full-year 2021 target of 58%, compared with 56% for 2020.
- Management expected operating expenses to rise above Q1 levels as it continued hiring and investing in growth; salaries and travel were expected to increase. These are management expectations, not quantified revenue or earnings guidance.
- Management reported no noticeable COVID-19-related revenue impact through the filing date, but said the future impact was uncertain. A sustained downturn could reduce customers’ advertising and marketing spending.
Risks, contingencies, and other items
- The filing identifies general forward-looking risks including economic conditions, regulation, access to capital, interest rates, competition, and accounting changes; it refers readers to the 2020 Form 10-K risk factors.
- The company reported no material pending legal proceedings, no off-balance-sheet arrangements, and no material subsequent events. In April 2021, it issued 19,664 shares for $167,729 from option exercises.
- Potentially dilutive options and restricted stock were excluded from diluted loss per share as antidilutive. The Q1 statements include $707,153 of stock-based and board compensation in operating expenses.
- Management concluded disclosure controls were effective and reported no material changes to internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether revenue growth and new enterprise and channel partnerships translate into sustained sales growth.
- Whether product and partner mix improves gross margin toward management’s 58% full-year target.
- How hiring, travel, data, and other growth investments affect operating expenses and profitability.
- Whether operating cash flow remains positive as working-capital balances and customer collections change.
- The effect of the public offering, option exercises, and outstanding equity awards on future share dilution.
- How COVID-19 and customer marketing-budget decisions affect demand; management said the future impact was not predictable.